Current Report Filing (8-k)
July 08 2020 - 3:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 7, 2020
NanoVibronix,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-36445
|
|
01-0801232
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
525
Executive Blvd., Elmsford, NY 10523
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (914) 233-3004
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
NAOV
|
|
Nasdaq
Capital Market
|
Item
8.01 Other Events.
On
July 7, 2020, NanoVibronix, Inc. (the “Company”) issued a press release announcing that effective June 22, 2020, it
has entered into a two-year exclusive agreement with Ultra Pain Products, Inc. for the distribution of the Company’s proprietary
PainShield™ devices and components through and by Durable Medical Equipment (DME) Distributors throughout the United States.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference
herein.
As
previously reported, the Company recently experienced a cybersecurity incident. Specifically, the Company believes that one or
two unauthorized third parties were able to use an email domain similar to the Company’s to convince two of the Company’s
vendors to send payments in the aggregate amount of approximately $308,000 to unauthorized bank accounts that should have been
sent to the Company. One of the vendors successfully reclaimed $78,000 of the fraudulent transfers and has deposited such amount
into the Company’s account, while the other vendor recently informed the Company that it has recovered the remaining $230,000
of the fraudulent transfers and expects to deposit such amount into the Company’s account.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
NANOVIBRONIX,
INC.
|
|
|
|
Date:
July 8, 2020
|
By:
|
/s/
Brian Murphy
|
|
Name:
|
Brian
Murphy
|
|
Title:
|
Chief
Executive Officer
|
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jul 2023 to Jul 2024